 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Michael DiStefano and Antal Zemplenyi.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.067 |
|
|
|
-
DiStefano MJ, McQueen RB, Zheng H, Gyamfi HG, Ameyaw D, Campbell JD, Zemplenyi A. Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program. Appl Health Econ Health Policy. 2026 Mar; 24(2):261-269.
Score: 0.967
-
DiStefano MJ, Pearson SD, Rind DM, Zemplenyi A. How Do the Institute for Clinical and Economic Review's Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee's Assessments of Added Benefit? A Qualitative Study. Value Health. 2024 08; 27(8):1066-1072.
Score: 0.874
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 Sep; 43(9):1147-1160.
Score: 0.237
-
Zemplenyi A, Leonard J, Wright GC, DiStefano MJ, Nair K, Anderson KE, McQueen RB. Innovative Payment Models for Sickle-Cell Disease Gene Therapies in Medicaid: Leveraging Real-World Data and Insights from CMMI's Gene Therapy Access Model. Pharmacoeconomics. 2025 May; 43(5):583-594.
Score: 0.231
-
DiStefano MJ, Zemplenyi A, Anderson KE, Mendola ND, Nair KV, McQueen RB. Alternative approaches to measuring value: an update on innovative methods in the context of the United States Medicare drug price negotiation program. Expert Rev Pharmacoecon Outcomes Res. 2024 Feb; 24(2):171-180.
Score: 0.215
-
DiStefano MJ, Zemplenyi A, McQueen RB. Assessing clinical benefit in the Medicare Drug Price Negotiation Program: A 2-step approach for improving transparency, consistency, and meaningful patient engagement. J Manag Care Spec Pharm. 2024 Mar 01; 30(3):252-258.
Score: 0.215
-
Zemplenyi A, Leonard J, DiStefano MJ, Anderson KE, Wright GC, Mendola ND, Nair K, McQueen RB. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid. Pharmacoeconomics. 2024 Mar; 42(3):319-328.
Score: 0.212
-
Nikitin D, Rind DM, McQueen B, Raymond F, Sanchez S, DiStefano MJ, Zemplenyi A, Lee W, Ollendorf D. The effectiveness and value of suzetrigine for moderate to severe acute pain: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council. J Manag Care Spec Pharm. 2025 Jul; 31(7):729-734.
Score: 0.059
-
Nikitin D, Mustafa RA, McQueen B, Zemplenyi A, DiStefano MJ, Nhan E, Kayali Y, Richardson M, Rind DM, Pearson SD, Agboola F. The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder. J Manag Care Spec Pharm. 2024 Oct; 30(10):1191-1195.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|